IL33 and neoplasm: The caveat with studies that include exogenous IL-33 as an alarmin is as follows: These studies may be restricted to a biological output primarily driven by IL-33/PD-1 axis and may not fully capture the function of PD-1 signaling that occurs in activated ILCs within the tumor or tissue microenvironment.